The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Group sales grow by 1% at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidance

From 2019 to 2022, the market experienced substantial growth, surging from $124.7 million to $1,155.6 million at an impressive Compound Annual Growth Rate (CAGR) of 110.1%. Projections indicate a continued expansion, reaching an estimated $75,568.8 million by 2030, albeit with a moderated CAGR of 39.2%, signaling a deceleration in market growth.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Techcyte, a world leader in artificial intelligence (AI)-based digital diagnostics, today announced a strategic collaboration agreement to offer an AI-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and precancer using whole-slide imaging.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Agilent Technologies Inc. (NYSE: A) today announced an agreement with Incyte that will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialization of Incyte’s hematology and oncology portfolio.

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023. All results in this release reflect only continuing operations unless otherwise noted.

Immunoassay is the largest subdivision in in vitro diagnosis and is in rapid develop-ment, in which chemiluminescence has gradually replaced enzyme-linked immuno-sorbent assay as the mainstream immune diagnosis in China.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with the Kenyan Government through the National Cancer Institute-Kenya to advance access to critical cancer diagnostics for women in Kenya. Through this program, BD continues to drive its commitment toward progress of advancing health equity to underserved communities around the world.

Next-generation sequencing (NGS) is a high-throughput method for DNA sequencing that has largely superseded traditional first-generation sequencing methods.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.